HOFFMANN-LA ROCHE

Company snapshot

HOFFMANN-LA ROCHE maintains 286 tracked programs across Breast Cancer, Multiple Sclerosis (MS), Spinal Muscular Atrophy (SMA), Non-Small Cell Lung Cancer, Solid Tumors, Rheumatoid Arthritis, Gastric Cancer, Carcinoma, Hepatocellular, Hepatitis C, Chronic, Not Applicable, Diabetes Mellitus Type 2, Early Breast Cancer. Momentum score: 20/100 (30-day delta: n/a). Public registry data covers pipeline

• 27 approved product(s) across US/EU regulatory metadata.
• 4 active pipeline program(s) linked via ClinicalTrials.gov.
• 286 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for HOFFMANN-LA ROCHE. Not investment advice.

• What is HOFFMANN-LA ROCHE?

  Hoffmann-La Roche is a pharma organization headquartered in Basel, CH. Primary therapeutic focus areas include Breast Cancer, Multiple Sclerosis (MS), Spinal Muscular Atrophy (SMA), Non-Small Cell Lung Cancer, Solid Tumors. NovaPharmaNews links 286 clinical program(s), 18 drug pr

• Is HOFFMANN-LA ROCHE publicly traded?

  HOFFMANN-LA ROCHE appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does HOFFMANN-LA ROCHE develop or market?

  We link 155 drug profile(s) where HOFFMANN-LA ROCHE is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/roche-registration-limited#company-drugs.

• What are the latest developments for HOFFMANN-LA ROCHE?

  In the last 12 months our linked public records show 286 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does HOFFMANN-LA ROCHE focus on?

  HOFFMANN-LA ROCHE focuses on Breast Cancer, Multiple Sclerosis (MS), Spinal Muscular Atrophy (SMA) based on our analysis of their pipeline programs and drug development activities.